Zydus Lifesciences has been granted a patent for a liquid oral pharmaceutical composition containing tadalafil for the treatment of conditions like pulmonary arterial hypertension and erectile dysfunction. The composition includes specific excipients and maintains a pH of about 5. GlobalData’s report on Zydus Lifesciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Zydus Lifesciences, NSAID cancer drugs was a key innovation area identified from patents. Zydus Lifesciences's grant share as of May 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11975006B2) discloses a liquid oral pharmaceutical composition containing approximately 4 mg/mL of tadalafil or a pharmaceutically acceptable salt, along with a wetting agent such as ethanol, glycerin, or propylene glycol, in an amount ranging from 100 mg/mL to 1000 mg/mL. The composition also includes water as a vehicle, with a pH of around 5. The tadalafil in the composition is specified to have a particulate size ranging from 1 micron to 200 microns, and the wetting agent can vary in concentration from 100 mg/mL to 800 mg/mL. Additionally, the composition may contain viscosity modifying agents, anti-foaming agents, pH adjusting agents, and surfactants in specified amounts to enhance its pharmaceutical properties.
Furthermore, the patent claims cover various methods for the treatment of conditions like pulmonary arterial hypertension, erectile dysfunction, and benign prostatic hyperplasia by administering the disclosed liquid oral pharmaceutical composition to patients in need. The composition's specific formulation, including the concentration of tadalafil, wetting agents, and other excipients, is tailored to provide a therapeutically effective amount for treating these conditions. The patent highlights the versatility and potential applications of the liquid oral pharmaceutical composition in addressing different medical conditions, emphasizing its role as a promising treatment option in the field of pharmaceuticals.
To know more about GlobalData’s detailed insights on Zydus Lifesciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
